Overview

A Study to Evaluate the Efficacy of Xlear vs. Placebo for Acute COVID-19 Infection

Status:
Withdrawn
Trial end date:
2021-08-30
Target enrollment:
Participant gender:
Summary
This study aims to find out the efficacy of Xlear nasal spray as an adjunct medication against COVID-19. This encompasses reduction in the number of days to negativization via nasal swab PCR from the average 14 days and early improvement of symptoms.
Phase:
Phase 3
Details
Lead Sponsor:
Larkin Community Hospital